内镜下射频消融联合新型口服5-氟尿嘧啶类药物对比单纯射频消融治疗不可切除肝外胆管癌
本研究将不可切除肝外胆管癌患者前瞻性随机分为RFA+S-1组(n=37)和单纯RFA组(n=38),比较两组中位总生存期、支架通畅时间、KPS评分及不良事件发生率。结果显示RFA+S-1组中位OS为16.0个月(95%CI 13.1-19.0),长于RFA组的11.0个月(95%CI 9.7-12.3)(P<.001),支架通畅时间及术后9、12个月KPS评分也更高,ERCP相关不良事件发生率两组无显著差异。
要点
- 不可切除肝外胆管癌患者中,RFA+S-1组中位OS 16.0个月,长于单纯RFA组的11.0个月(P<.001)。
- RFA+S-1组支架通畅时间6.6±1.5个月,长于RFA组的5.6±.1个月(P=.014)。
- 两组ERCP相关不良事件发生率无显著差异(8.1% vs 10.5%,P>.05)。
核心结论
- 对于局部晚期不可切除肝外胆管癌,内镜下RFA联合S-1较单纯RFA与更长的生存期、支架通畅时间及改善的功能状态相关。
研究设计与样本
- 前瞻性随机对照研究,将不可切除肝外胆管癌患者随机分为RFA+S-1组(n=37)和RFA组(n=38)。
- 分析指标包括中位总生存期、支架通畅时间、KPS评分及不良事件发生率。
- 临床试验注册号:NCT02592538。
主要发现
- RFA+S-1组中位OS为16.0个月(95%CI 13.1-19.0),RFA组为11.0个月(95%CI 9.7-12.3),RFA+S-1组较RFA组延长(P<.001)。
- RFA+S-1组支架通畅时间为6.6±1.5个月,RFA组为5.6±.1个月,RFA+S-1组较RFA组延长(P=.014)。
- 术后9个月KPS评分RFA+S-1组为51.6±17.0,RFA组为40.4±16.4,RFA+S-1组较高(P=.012)。
- 术后12个月KPS评分RFA+S-1组为35.2±18.3,RFA组为23.9±11.4,RFA+S-1组较高(P=.014)。
- ERCP相关不良事件发生率RFA+S-1组为8.1%,RFA组为10.5%,两组无显著差异(P>.05)。
关键数值与推荐
- RFA+S-1组中位OS 16.0个月(95%CI 13.1-19.0)vs RFA组11.0个月(95%CI 9.7-12.3),P<.001。
- RFA+S-1组支架通畅时间6.6±1.5个月 vs RFA组5.6±.1个月,P=.014。
- 术后9个月KPS评分RFA+S-1组51.6±17.0 vs RFA组40.4±16.4,P=.012。
- 术后12个月KPS评分RFA+S-1组35.2±18.3 vs RFA组23.9±11.4,P=.014。
- ERCP相关不良事件发生率RFA+S-1组8.1% vs RFA组10.5%,P>.05。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Endoscopic radiofrequency ablation (RFA) is a new ablative treatment for unresectable extrahepatic cholangiocarcinoma (EHCC). A novel 5-fluorouracil compound, S-1 (Taiho Pharmaceutical Co, Ltd, Tokushima Plant. Japan), has been widely used as a key drug with first-line or second-line chemotherapy for the treatment of advanced cholangiocarcinoma. The aim of this study was to evaluate the clinical efficacy and safety of endoscopic RFA combined with S-1 for the treatment of unresectable locally advanced EHCC. METHODS: Patients with unresectable EHCC were prospectively randomized to 1 of 2 groups: the RFA + S-1 group and the RFA group. Median overall survival (OS), stent patency time, Karnofsky performance status (KPS) score, and adverse events rate were analyzed. RESULTS: The median OS was longer in the RFA + S-1 group (n = 37) than that in the RFA group (n = 38) (16.0 months [95% confidence interval, 13.1-19.0] vs 11.0 months [95% confidence interval, 9.7-12.3]; P < .001). Stent patency time was significantly longer in the RFA + S-1 group than that in the RFA group (6.6 ± 1.5 vs 5.6 ± .1 months, P = .014). KPS scores at postoperative month 9 (51.6 ± 17.0 vs 40.4 ± 16.4, P = .012) and month 12 (35.2 ± 18.3 vs 23.9 ± 11.4, P = .014) were all higher in the RFA + S-1 group than those in the RFA group (P < .05). The incidence of ERCP-related adverse events was not significantly different between RFA+S-1 and RFA groups (8.1% vs 10.5%, P > .05). CONCLUSIONS: For the treatment of locally advanced EHCC, endoscopic RFA combined with S-1 is associated with longer survival and stent patency and improved functional status than RFA alone. (Clinical trial registration number: NCT02592538.).
引用
- Yang J, Wang J, Zhou H, et al. Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma. Gastrointest Endosc. 2020. PMID: 32437711. doi:10.1016/j.gie.2020.04.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。